Researchers at Weill Cornell Medicine have gleaned new insights on the ways cells maintain the tips of their chromosomes, or telomeres. The findings help illuminate a wide range of phenomena, from cancer development to fungal evolution.
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The immunotherapy drug pembrolizumab, known by its brand name Keytruda, is a safe and effective option for patients with locally advanced and metastatic squamous cell esophageal cancer who have already received standard chemotherapy, according to a new study co-authored by a Weill Cornell Medicine and NewYork-Presbyterian investigator.
Space travel, illnesses like COVID-19, and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and many other investigators.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, has been awarded a four-year, $600,000 Distinguished Scientist grant by the Sontag Foundation to study the diversity of cell types within brain cancers called gliomas.
Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research.
A team led by Weill Cornell Medicine scientists has pioneered a method for manufacturing functioning human blood vessels and demonstrated that they can carry blood in lab-grown model organs and tumors.
A preclinical model of a common type of breast cancer provides new insight into why an immunotherapy known as checkpoint inhibition has not yet been effective against the cancer
The greatly increased risk of cancer and cancer mortality with aging may be due in part to the buildup in the body of a key cancer-promoting molecule, according to new preclinical research from scientists at Weill Cornell Medicine.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, has been named a 2020 Vallee Scholar by the Vallee Foundation.
Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering.
A new set of laboratory models designed to study variations in one of the most commonly mutated genes in cancer has revealed that each variation has a different effect on the colon and pancreas, according to investigators at Weill Cornell Medicine. The models also provide a new platform for screening potential therapies.
Localized radiation therapy against a tumor can trigger a beneficial immune response throughout the body by releasing DNA from mitochondria into the cytoplasm of tumor cells, according to new preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Weill Cornell Medicine and NewYork-Presbyterian have realigned the Department of Healthcare Policy and Research to address the intersection of research and practice. The newly named Department of Population Health Sciences, led by distinguished health services researcher, information scientist and leader Dr. Rainu Kaushal, aims to improve the health of populations through data-driven research, innovative technology and novel education programs.
A code discovered in DNA packaging proteins enables the rapid expression of genes needed to fight immediate threats, a finding that may pave the way for new treatments for cancer and inflammatory diseases.
A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).
A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
